David P. Schenkein - 03 Jun 2026 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Reporting relationship: Director
Issuer ticker: DNLI
Reported as of: 03 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2026, 16:45:26 UTC
Prior SEC filing: 06 Jan 2026
Next SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Tyler Nielsen, by power of attorney

Key filing fact

David P. Schenkein filed Form 4 for Denali Therapeutics Inc. (DNLI) on 05 Jun 2026.

Key facts

This page summarizes David P. Schenkein's Form 4 filing for Denali Therapeutics Inc. (DNLI).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2026, 16:45.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001578200 Primary reporting owner

Schenkein David P

Relationship: Director
Address: C/O DENALI THERAPEUTICS INC., 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Signature: /s/ Tyler Nielsen, by power of attorney
Signature date: 05 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNLI transaction

Common Stock

Award

Transaction value
Shares: +6,408
Change %: +42%
Price: $0.000000^*
Shares after: 21,665
Date: 03 Jun 2026
Ownership: Direct
Footnotes: F1, F2

DNLI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 26,232
Date: 03 Jun 2026
Ownership: See footnote
Footnotes: F3

DNLI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 31,232
Date: 03 Jun 2026
Ownership: See footnote
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNLI transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +19,226
Change %
Price: $0.000000^*
Shares after: 19,226
Date: 03 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,226
Exercise price: $19.66
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

Footnote F2

Includes 6,408 unvested RSUs.

Footnote F3

The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee.

Footnote F4

The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person's spouse serves as a trustee.

Footnote F5

100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.